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INTRODUCTION 
Neonatal sepsis is a major and frequent cause of 
morbidity and mortality in the neonatal period. 
Early diagnosis and treatment are crucial to an 
improvement in prognosis. Clinical findings are 
usually nonspecific and indistinguishable from 
those caused by a variety of neonatal noninfective 
disorders. Therefore, markers are needed that 
reliably identify truly infected neonates1,2.  
Original article 
Background: The majority of monocytes (MO) are strongly positive for 
CD14 and negative for CD16. The phenotype and function of peripheral 
blood monocytes change after trauma and during sepsis. CD14+CD16+ 
monocytes, identified as a minor population of monocytes which  constitute 
a potent phagocytosing and antigen-presenting monocyte subpopulation that 
expands during acute and chronic infections. 
Objective: To evaluate monocyte expression of  CD14 and CD16 in preterm 
neonates and to assess it as a possible marker for early diagnosis of 
neonatal sepsis  as the early clinical signs are often insidious and non-
specific.  
Methods: This study was carried out on 45 preterm neonates (1-3 days old ) 
with a mean  gestational age  of 34.5 ± 1.03 weeks . They were classified 
into three groups. Group I included 15 neonates with proven sepsis. Group 
II included 15 neonates with possible or suspected infection. Group III 
(control group) included 15 healthy age and sex matched neonates. The 
neonates with possible infection were followed up. Nine of them developed 
sepsis later on (proved clinically and by laboratory) and they were 
considered as patients with early sepsis at the time of admission. History 
taking and clinical examination were performed as well as laboratory 
investigations including, complete blood count, blood culture and sensitivity 
(for patients only), measurement of C-reactive protein (CRP) and CD14 and 
CD16 expression on monocytes by flow cytometry. 
Results: The proportion of CD14+ CD16+ MO within all circulating 
monocytes was significantly higher in patients with proven (75.2±13.1%), 
early (63.9±17.9%) or possible sepsis (55.1±26.8%) than controls 
(3.86±2.53%)   (p<0.0001, p<0.0001, p<0.001, respecctively). It was higher 
in neonates with proven than possible sepsis ( p<0.05), whereas it was 
comparable in the groups of proven and early sepsis  (p>0.05).  There was a 
significant positive correlation between mean fluorescence intensity (MFI) 
of CD16+ MO and CRP ( p<0.01) and a significant negative correlation 
between it and the platelet count ( p<0.05) among  patients. When neonates 
with early sepsis were followed up after 48 hours a significant increase in 
CRP levels and MFI of CD16 expression on monocytes was noted (p<0.01 
for both). The sensitivity and negative  predictive value of CD14+ CD16+ 
MO% and MFI of CD16+ MO were higher than that of CRP. Specificity and 
positive predictive value of CD14+CD16+ MO% were similar to those of 
CRP. The cut off point (obtained from the ROC curve) for CD14+ CD16+ 
MO% was 8.6% and that for MFI of CD16+ MO was 9. 
Conclusion: The measurement of the percentage of CD14+ CD16+ MO 
among circulating MO is a promising rapid and sensitive test for early 
diagnosis of neonatal sepsis  and exclusion of infection in neonates with 
high risk to develop sepsis. NICU costs as well as unnecessary antibiotic use 
can be thus reduced.  
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Peripheral blood monocytes (MO) are members 
of the mononuclear phagocytic system, which play 
a central role in immunoregulation and host defense 
against immunopathogenic organisms. They are 
heterogeneous in phenotype and function3. Many 
monocyte antigens serve as receptors for 
recognition and processing of bacterial antigens. 
The CD14 membrane antigen functions as a 
receptor for lipopolysaccharides (LPS) from gram-
negative bacteria and triggers LPS-induced 
monocyte activation4-6.  Moreover, CD14 seems to 
be involved in the recognition of structures from 
gram-positive bacteria such as lipoteichoic acid and 
peptidoglycan7,8. In addition, receptors for the 
fragment crystallisable (Fc) region of IgG are 
important in the intracellular phagocytosis of IgG-
opsonized microorganisms9.  The Fc gamma 
receptor III (Fcγ R III) (CD16) exists in two 
polymorphic forms: the transmembrane from (Fcγ 
RIIIa) expressed in monocytes/ macrophages and 
the glycosyl phosphatidylinositol-anchored form 
(Fcγ RIII b) expressed in granulocytes9. The Fcγ 
RIIIa form on monocytes is reported to mediate 
important immunophysiological functions such as 
superoxide generation10 and antibody-dependent 
cell mediated cytotoxicity11, and signal transduction 
by Fcγ receptor type III is mediated through the γ 
chain of the Fcγ receptor type III complex12.  
CD 14 is a specific marker for the cells of the 
monocyte/macrophage lineage refered to as 
mononuclear phagocytes (MNPs)13. According to 
the extent of expression of the CD14 antigen on the 
monocytes, the monocytes are separated into two 
subpopulations: CD14high monocytes (monocytes 
expressed CD14 at a high density) and CD14dim 
monocytes (monocytes expressed CD14 antigen at 
a lower level)14.  
The majority of peripheral blood monocytes 
strongly positive for CD14 are negative for CD16. 
However, a subset of monocytes has coexisting 
CD14 and CD16 known as CD14+CD16+ 
monocytes. The CD14+ CD16+ MO are considered 
to represent an activated, more mature, 
“macrophage-like” subset15,16. This subpopulation 
greatly expands in various infectious and 
inflammatory diseases, including acquired 
immunodeficiency syndrome (AIDS), asthma, 
chronic infections in haemodialysed patients and 
sepsis17-19. The increased proportion and absolute 
number of CD14+ CD16+ MO correlate with the 
presence of bacteria in the blood and are preceded 
by cytokine production20. Owing to this, the 
determination of the proportion of CD14+ CD16+ 
MO level was suggested as useful for monitoring of 
patients with high risk of sepsis21. 
To our knowledge, the changes of CD16 
expression on MO of preterm newborns during 
infection or sepsis have not been studied before. So, 
this study was undertaken to evaluate monocyte 
expression of CD14 and CD 16 in neonates and to 
assess it as a marker of early-onset neonatal 
infection. This may be helpful in early and accurate 




This study was carried out in the neonatal intensive 
care unit (NICU) of Benha Children Hospital 
together with Pediatrics and Clinical Pathology 
Departments in Ain Shams University Hospitals. It 
was conducted in the period from April 2003 till 
February  2004.  
The study comprised 30 neonates with possible 
or proven sepsis and 15 age and sex matched 
neonates with no clinical or laboratory findings 
suggestive of sepsis as a control group. All were 
preterms with gestational age ranging between 33-
36 weeks and a mean of 34.53 ± 1.14 weeks. Their 
ages ranged between 1-3 days with a mean of 1.23 
± 0.5 days. They were divided into 2 groups (I & II) 
as follows.  
Group I (group of neonates with proven sepsis):  
It comprised 15 neonates admitted to NICU with 
proven neonatal sepsis. All had clinical picture 
suggestive of sepsis and a positive blood culture. 
They were 8 (53%) males and 7(47%) females. 
Their ages ranged between 1-3 days with a mean of 
1.47 ± 0.64 days. 
Group II (group of possible or suspected 
infection):  
It comprised 15 neonates with possible or suspected 
sepsis i.e. with two or fewer of the following 
categories of clinical signs of sepsis: 
-Respiratory dysfunction (apnea, cyanosis, grunting 
and intercostal retraction).  
-Circulatory dysfunction (tachycardia, poor 
perfusion and shock).  
-Neurological dysfunction (hypotonia, irritability 
and lethargy).  
-Gastrointestinal dysfunction (feeding intolerance, 
abdominal distension, hepatomegaly and jaundice).  
All had initially negative blood culture ± abnormal 
leukocytic count or high CRP.  
There was a high risk factor for infection (as 
premature rupture of membranes (PROM) > 18 
hours, chorioamnionitis, intrapartum maternal fever 
> 38 ºC, maternal history of urinary tract infection, 
vaginal bleeding and/or complicated traumatic 
delivery).  
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They were 8 (53%) males and 7 (47%) females, 
in their first day of life.  
Group III (control group) 
It included 15 healthy age and sex-matched 
newborns with no clinical manifestations or 
laboratory findings denoting neonatal sepsis. They 
were 6 males (40%) and 9 females (60%). Their 
ages ranged between 1-2 days with a mean of 1.33 
± 0.49 days.  
 
Study design: 
Patients and controls were subjected to the 
following:  
I- History taking: Laying stress on antenatal, natal 
and postnatal periods to detect risk factors for 
neonatal infection as premature rupture of 
membranes > 18 hours, maternal fever >38 ºC, 
vaginal bleeding or presence of foreign body as 
endo-tracheal or chest tubes and mode of delivery 
(vaginal, cesarean section or complicated 
traumatic). 
II- Clinical examination:  
a- To detect clinical signs of sepsis that have been 
previously mentioned.  
b- General examination (laying stress on) :  
- Weight, length, skull circumference.  
- Vital signs (pulse, temperature, blood pressure, 
respiratory rate).  
- Neonatal reflexes (Moro’s, grasping and 
suckling).  
III- Laboratory investigations which included:  
* Complete blood count and blood smears for 
differential count.  
* Blood culture and sensitivity.  
* C-reactive protein.  
* Assessment of CD 14 and CD16 expression on 
monocytes by flow cytometry and measuring the 
percentage of CD14+ CD16+ monocytes within all 
circulating monocytes.  
Patients with possible sepsis were followed up 
to detect the development of other clinical 
manifestations of sepsis. CRP was repeated after 24 
and 48 hours and blood culture was repeated after 
48 hours. The patients who developed sepsis later 
as evidenced by clinical manifestations of sepsis 
listed above and positive blood culture were 
considered as patients with early sepsis at the time 
of admission (n=9).  
Methods: 
Sample collection:  
Three ml of venous blood were collected from each 
preterm newborn under aseptic conditions. Two ml  
were dispensed into tubes containing K- EDTA as 
an anticoagulant, one ml was immediately used for 
flow cytometric analysis and one ml was taken for 
complete blood count. The remaining one ml was 
left to clot, then centrifuged and the separated 
serum was used for CRP assay.  
Complete blood count:  
Blood samples were assayed by coulter counter on 
the same day (Coulter Microdiff 18, USA), it 
included (total leukocytic count, absolute 
neutrophilic count, immature / total neutrophilic 
ratio (I/T ratio), red blood cell count, hemoglobin 
level and platelet count. Leishman stained 
peripheral blood films were done for all samples 
and examined for differential blood count laying 
stress on neutrophil number and band cell number.  
C-reactive protein (CRP): 
CRP was measured semi-quantitatively using latex 
agglutination test kit (Avitex-CRP Omega 
Diagnostics Ltd. , UK ). The cut-of point of CRP is 
6 mg/L22. 
Flow cytometric analysis :  
Fluorescein isothiocyanate (FITC) labeled anti 
CD14 monoclonal antibodies (CD14 - FITC) and 
phycoerythrin (PE) labeled anti CD16 monoclonal 
antibodies (CD16-PE) were used in the present 
study (Cymbus Biotechnology LTD, Hamsphere, 
U.K), together with FITC and PE negative isotype  
(Cymbus Biotechnology LTD, Hamsphere, U.K) 
controls (in order to determine the non specific 
binding of monoclonal antibodies under study).  
Total leukocyte count (TLC) in each blood 
sample was adjusted at 5-10x103 cell/ ul and 100 ul 
of each sample were added to a tube containing 10 
ul of each of CD14-FITC and CD16-PE, then tubes 
were gently vortexed and were incubated for 15 
minutes in the dark. One ml of working lysing 
solution (ammonium chloride 1.5 mmol/l, 
potassium biphosphate 100 mmol/l and tetrasodium 
EDTA 10 mmol/L) was added to each tube which 
was vortexed and incubated again for 5-10 minutes, 
followed by centrifugation at 3000 rpm for 5 
minutes. The supernatant was then discarded and 
tubes were washed twice with phosphate buffered 
saline (PBS) and cells were then resuspended in 
300 ul of PBS and analysed using Coulter Epics XL 
flow cytometer (Profile  Instrument, Coulter 
Electronics, Hieloch, FL. USA). 
Monocytes were gated by forward and side 
scatter and CD14, CD16 expression was then 
assessed on the gated monocytes. CD14high 
(CD14bright) and CD14dim, CD16 expressing cells 
were then electronically determined. Results were 
expressed by percent of cells co-expressing both 
markers CD14 and CD16 within all circulating 
monocytes in comparison to isotype matched 
control and by mean fluorescence intensity (MFI) 
of CD16 expression on the CD14 gated monocytes.  
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Statistical methods:  
The results were analyzed by commercially 
available software package (Stat View, Abacus 
Concepts, Inc, Berkley, CA, USA). The data are 
presented as mean, standard deviation (SD), median 
and interquartile range (IQR). IQR is the range 
between 25th percentile till 75th percentile. Student’s 
“t” test was used for comparing parametric data   
between each two groups, whereas Mann-Whitney 
U test was used for non-parametric data. Wilcoxon 
signed rank test (for non parametric data) was used 
to compare between the same group in two repeated 
measurements such as the initial results of the 
group of early sepsis versus the results after 48 
hours. Correlation between variables was 
determined by Spearman’s rank correlation 
coefficient. Chi square test was used to compare 
between categorial variables. After analysis, a 
probability p value <0.05 was considered 
significant.  
The diagnostic performance of a variable 
(ability to discriminate between 2 conditions) was 
evaluated using Receiver Operating  Characteristic 
(ROC) curve analysis. The ROC curve is a graph of 
the true positive rate (Sensitivity) against the false 
positive rate (1- specificity) at different cut-off 
points. The optimal cut-off point is the point that 
gives the highest sensitivity and specificity.  
 
RESULTS 
CD14 and CD16 expression on monocytes in the 
different groups:  
Range, mean, SD, median and IQR of the 
following: proportion of CD14+ CD16+ monocytes 
within all circulating monocytes (CD14+ CD16+ 
MO %), Mean fluorescence intensity of  CD16 
expression on the  CD14 gated monocytes (MFI), 
proportion  of  CD14dim   CD16+ MO and  CD14high   
CD16+  MO within all circulating monocytes are 
shown in table (1).  
A set of histograms that represent flow cytometric 
analysis of CD14 and CD16 expression on 
monocytes is shown in figure (1).  
The percentage of CD14+CD16+MO was 
significantly higher in patients with proven, early 
and possible sepsis than controls (z = 4.67, 
p<0.0001; z = 4.02, p<0.0001; z = 3.57, p<0.001, 
respectively). It was higher in neonates with proven 
than possible sepsis (z = 2.3, p<0.05), whereas there 
was no significant difference between the groups of 
proven and early sepsis (z = 1.64, p>0.05) (Fig. 
2A). 
Mean fluorescence intensity of CD16 
expression on the CD14 gated monocytes (MFI of 
CD16+MO) was higher in neonates with proven 
sepsis and early sepsis than controls (z = 3.84, 
p<0.0001; z = 4.02, p<0.0001, respectively), 
whereas it was comparable in the group of possible 
infection and controls (z = 1.87, p>0.05). It was 
significantly higher in neonates with proven sepsis 
than those with early and possible infection (z = 
2.3, p<0.05; z = 3.38, p<0.001 respectively) (Fig. 
2B). 
 
The prevailing subset of monocytes in patients and 
controls 
There was no significant difference in the 
prevalence of CD14high CD16+ MO and CD14dim 
CD16+ MO among patients and controls. 
Percentage of CD14high CD16+ MO was higher than 
that of CD14dim  CD16 MO in both patients and 
controls (Table 2, Fig. 3). 
 
Correlation between CD14 & CD16 expression on 
monocytes and clinical characteristics of patients 
and controls: 
There was no significant correlation between 
CD14+ CD16+ MO% and gestational age, age or 
weight neither in the studied patients (r = -0.09, 
p>0.05; r = 0.04, p>0.05; r = -0.18, p>0.05, 
respectively) nor in the control group (r = 0.2, 
p>0.05; r = -0.08, p>0.05; r = 0.13, p>0.05, 
respectively).  
There was no significant difference between males 
and females as regards CD14+ CD16+ MO% neither 
in the studied patients nor in the control group (z = 
0.5, p>0.05; z = 0.71, p>0.05, respectively).  
 
Correlation between CD14 & CD16 expression on 
MO and indices of neonatal sepsis. 
Table (3) shows that there was a significant positive 
correlation between MFI of CD16+ MO and CRP 
(Fig. 5); and significant negative correlation with 
RBCs count and platelets count. While there was a 
significant positive correlation between CD14dim 
CD16+ MO% and CRP level in the studied patients, 
whereas there was no significant correlation 
between CD14+ CD16+ MO% or CD14high CD16+ 
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CD14+ CD16+ MO% * 
Range 52.5-95.4 2.01-94.2 42-94.2 0.6-8.6 
Mean ± SD 75.24±13.12 55.19±26.8 63.92±17.9 3.86±2.53 
Median 74 59.7 63.2 2.3 
IQR 64.95-85.6 44.15-74.8 49.6-75.1 2.15-6.55 
MFI of  CD16+ MO 
Range 11.8-58.7 1.7-21.7 10.2-21.7 1-19.1 
Mean ± SD 28.53±14.62 12.58±5.61 15.89±3.7 8.28±6.78 
Median 24.7 12.3 16.4 6.7 
IQR 16.5-36.65 9.5-17 14.9-17.8 2.35-14.85 
CD14dim CD16+ MO% * 
Range 7.8-56.5 0.6-20 6.6-13.5 0.08-2.1 
Mean ± SD 19.53±14.48 10.45 ± 4.39 10.82 ± 2.44 0.98 ±0.75 
Median 14.4 11.8 12 0.6 
IQR 10.35-20.6 8.3-12.2 8.9-12.1 0.55-1.7 
CD14high CD16+ MO%* 
Range  6.4-78.8 1.1-60 33-60 0.4-6.2 
Mean ± SD 44.39±23.71 39.67 ±16.27 46.61±10.81 2.36 ±1.58 
Median 48.5 41.2 42 1.6 
IQR 26.75-63.7 34.5-48.55 39-59 1.35-3.5 
*: % of all circulating monocytes. SD: Standard deviation. IQR: Interquartile range  
 
(A) Gating of monocytes by forward & 
side scatter 
(B) CD14+ CD16+ monocytes in a 
control neonate [2.2%] 
(C) CD14+ CD16+ monocytes in a 
neonate with proven sepsis [77.2%] 
   
   
(D) CD14+ CD16+ monocytes (2nd 
example) of proven sepsis [79.2%] 
(E) CD14+ CD16+ monocytes in a 
neonate with early sepsis [64.9%] 
F) CD14+ CD16+ monocytes in the 
previous case after 48 hr. [86.4%] 
  
 
Figure 1: A set of histograms that represent flow cytometric analysis of CD14 and CD16 expression on 
monocytes. Upper and lower right quadrants  (2 & 4) represent all CD14+ cells, upper right and left quadrants (1 & 2) 
represent all CD16+ cells, upper right quadrant (2) represents cells having coexpression of both CD14 & CD16. Square in (A) 
represents the forward scatter (FS) and side scatter (SS) gated monocytes. Squares C  & D in (C), (D), (E) and (F) represent 
CD14dim  CD16+MO, CD14highCD16+ monocytes respectively. The percentage of CD14+CD16+ monocytes is given in 
parentheses.  





Figure 2: Comparison of CD14+ CD16+ MO (A) and MFI of CD16+ MO (B) among the  studied 
groups. Horizontal lines indicate median values and boxes enclose interquartiles (25th and 75th 
percentiles). Ranges are marked as maximum and minimum, and dots represent mean values. Mann- 
Whitney U test is used in comparison. ## Highly significant difference with the control group (p < 0.01). 
 
 
Table 2: Comparison of prevalence of CD14high CD16+ MO & CD14dim CD16+ MO among all 
studied patients and controls. 
CD14dim CD16+MO /CD14high CD16+ MO 
All patients 
(n = 30) 
Controls 
(n = 15) 
Total 
(n = 45) Chi-square p n % n % n % 
CD14highCD16+MO> CD14dim CD16+MO                    28 93% 15 100% 43 96% 1.05 >0.05 CD14dimCD16+MO>  CD14high CD16+MO 2 7% 0 0% 2 4% 
 
 
Table 3: Correlation between CD14 & CD16 expression on monocytes and laboratory indices 
of neonatal sepsis in all studied patients. 
Parameter   CD14
+CD16+ 
MO% 






Hb (gm/dL) r -0.17 -0.20 - 0.14 -0.25 p > 0.05 > 0.05 > 0.05 > 0.05 
RBCs (x106/mm3) r -0.16 -0.39 -0.08 -0.13 p > 0.05 < 0.05* > 0.05 > 0.05 
TLC (x103/mm3) r -0.05 -0.06 -0.34 0.17 p > 0.05 > 0.05 > 0.05 > 0.05 
ANC (x103/mm3) r 0.17 0.01 -0.17 0.20 p > 0.05 > 0.05 > 0.05 > 0.05 
Immature neutrophils 
(x103/mm3) 
r 0 0.02 -0.22 0.16 
p > 0.05 > 0.05 > 0.05 > 0.05 
I/T ratio r 0.21 0.14 0.26 0.09 p > 0.05 > 0.05 > 0.05 > 0.05 
Platelets (x103/mm3) r -0.32 - 0.36 -0.33 -0.16 p > 0.05 < 0.05* > 0.05 > 0.05 
CRP 
(mg/L) 
r 0.17 0.55 0.40 -0.1 
p >0.05 <0.01** <0.05* >0.05 
p > 0.05=   Not significant, p < 0.05*=  Significant, p < 0.01, 0.001, 0.0001**=  Highly Significant  
Hb=hemoglobin, RBCs=red blood cells, TLC=total leukocytic count, ANC=absolute neutrophilic count, I/T ratio=immature/total 
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Table 4: Comparison between the initial results of CRP and CD14 & CD16 
expression on monocytes and the results after 48 hrs (at the time of positive 
blood culture) in the group of early sepsis.  
Parameters 
 
Initial After 48 h z p Mean ± SD Mean ± SD 
CRP 22.67 28.74 72 54.99 2.67 <0.01** 
CD14+ CD16+MO% 63.92 17.9 67.4 15.69 0.65 >0.05 
MFI  of CD16+ MO 15.89 3.7 23.73 4.99 2.67 <0.01** 
CD14dim CD16+MO% 10.82 2.44 12.97 6.21 1.24 >0.05 
CD14high CD16+MO% 46.61 10.81 47.98 13.11 0.3 >0.05 
z:  Wilcoxon signed rank test. p > 0.05 = Not significant, p < 0.05*=Significant, p < 0.01, 0.001, 0.0001**= Highly Significant  
 
Table 5: Sensitivity, specificity and predictive values of CRP, CD14+ CD16+ MO and 







+ve predictive  
value 
-ve predictive  
value 
CRP > 6 83.3 100 100 78.9 
CD14+ CD16+ MO% > 8.6 100 100 100 100 
MFI of CD16+ MO > 9 100 66.7 82.8 100 
+ve = positive, -ve = negative 
 
Figure 3: The proportion of CD16+ monocytes with 
dim and high expression of CD14 among the 
studied groups. Horizontal lines indicate median values 
and boxes enclose interquartiles (25th and 75th 
percentiles). Ranges are marked as maximum and 
minimum, and dots represent mean values. Mann- 
Whitney U test is used in comparison. 
 
 
Follow up of neonates with early sepsis 
When neonates with early sepsis were followed up 
for 48 hours, a significant increase in CRP levels 
and MFI of CD16 expression on monocytes was 
noticed, whereas no significant difference in CD14+ 
CD16+ MO%, CD14dim CD16+ MO% and CD14high 
CD16+ MO% was found (table 4). 
 
 
Sensitivity, specificity and predictive values of 
CD14+CD16+MO 
When the patients with proven and early sepsis 
were compiled as the positive group and the 
controls were considered as the negative group, the 
cut off point (obtained from the ROC curve) for 
CD14+ CD16+ MO% was 8.6% and that for MFI of 
CD16+ MO was 9. The sensitivity and negative 
predictive value of CD14+ CD16+ MO% and MFI 
of CD16+ MO were higher than that of CRP. The 
specificity and positive predictive value of 
CD14+CD16+ MO% were similar to those of CRP, 
whereas those for MFI of CD16+ MO were less 
than the corresponding parameters of CRP (table 5).  
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Figure 4: Correlation of MFI of CD16+MO with 
CRP among studied patients. 
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DISCUSSION 
The CD14+ CD16+ monocytes are considered to 
represent an activated more mature, “macrophage-
like subset” as opposed to the prevailing CD14+ 
CD16- MO15,16. This subpopulation greatly expands 
in various infections and inflammatory diseases 
including sepsis17-19. 
Our results revealed that CD14+CD16+ MO% 
was significantly increased in neonates with proven 
sepsis and early sepsis than in the control neonates. 
These CD14+CD16+ cells comprised 3.86 ± 2.53% 
of all circulating monocytes in the control group, 
and comprised 75.24 ± 13.12% and 63.92 ± 17.9% 
in the groups of proven sepsis and early sepsis 
respectively. 
In agreement with our results, Fingerle et al.23  
reported that in adult patients with septicemia, 
CD14+CD16+ MO became the predominant cell 
type and accounted for more than 50% of all 
monocytes while in the control group these cells 
accounted for 9.3% ± 5.2 % of all monocytes.  
Similarly, Nockher and Scherberich18 reported 
that CD14+CD16+ monocytes accounted for 8% ± 
4% of all monocytes in healthy adult controls of 
their series. In their hemodialysed patients suffering 
from chronic infection, these CD14+CD16+ cells 
constituted 24% of all blood monocytes. 
After trauma and during sepsis, significant 
monocytosis was observed24,25. In the present study 
monocytes % within all leukocytes was 
significantly higher in the neonates with proven 
sepsis (11.14 ± 3.87%) than controls (7.42 ± 
2.01%). In accordance with our results 
Skrzeczynska et al.26 reported that CD14+ cells 
comprised about 15% of all nongranulocytes (gated 
PBMCs) in the control group, 21% in children with 
clinical symptoms suggesting sepsis and 23% in 
children with symptoms of sepsis and positive 
blood culture. They postulated that the higher 
proportion of CD14+ cells within PBMCs in 
patients with symptoms of sepsis is due to the 
increased proportion of CD14+CD16+ MO. 
In the current study, CD14+CD16+ MO% was 
significantly elevated in patients with proven sepsis 
and early sepsis compared with the control group. 
This agrees with the findings of Skrzeczynska et 
al.26. They found that, CD14+CD16+ MO% was 
significantly increased both in samples obtained 
from patients with positive blood culture and in 
those with clinical symptoms of sepsis as compared 
to controls. They also found that, the risk group was 
comparable to controls. Their study included thirty 
children with median age of 4 months (range 5 days 
to 2 years) admitted to the intensive care unit. All 
children in their study were considered to be at high 
risk of developing sepsis based on their clinical 
condition such as burns over 30%, trauma or major 
surgical treatment owing to correction of congenital 
defects. To our knowledge our study is the first to 
elucidate the changes of CD14 and CD16 
expression on MO in preterm neonates. 
To exclude the possibility that underlying 
disease, drug treatment or intensive care treatment 
in themselves might induce the CD14+CD16+ cells, 
Fingerle et al.23 have screened a panel of 155 
patients with various conditions. These included 
patients with cardiovascular, inflammatory , 
infectious (viral and bacterial), metabolic and 
neoplastic diseases. In addition, they have tested 
113 ICU patients without sepsis syndrome. None of 
these patients exhibited increased CD14+CD16+ 
cells.  
We found that the mean CD14+CD16+ MO% 
was higher in neonates with proven sepsis than in 
the early sepsis group, however the difference did 
not reach statistical significance. Meanwhile, MFI 
of CD16+ MO was significantly higher in neonates 
with proven sepsis than the early sepsis group. 
Fingerle et al.23 reported that the increase of 
CD14+CD16+ cells in sepsis was not a persistent 
phenomenon, but usually lasted for only 1 to 3 days 
within a two weeks time span of screening. Low 
CD14 on monocytes was not a constant 
phenomenon either, but specific fluorescence 
intensity for CD14 was frequently still low when 
CD14+CD16+  cells had returned to the control 
range. Also, Skrzeczynska et al.26 reported that, the 
individual variations were significant, indicating 
that single measurements of CD14+CD16+  MO 
proportion are of limited diagnostic value. In 
contrast, repeated determinations proved useful. 
This statement was proved in our study when we 
measured CD14 and CD16 expression on 
monocytes twice in the group of early sepsis, on 
admission and after 48 hours. We found that mean 
fluorescence intensity of CD16 expression on the 
CD14+ monocytes (MFI) after 48 hours is 
significantly higher than the initial results. 
However, there was no significant difference 
between the results after 48 hours and initial results 
as regards CD14+CD16+ MO%, CD14dim CD16+ 
MO% and CDhigh CD16+ MO%. This suggests that 
MFI of CD16 expression on monocytes increases 
with progression of sepsis. 
     According to Murphy and Reen27  ,the majority 
of cord and adult monocytes expressed CD14 at a 
high density (CD14high) while approximately 15% 
of monocytes expressed this antigen at a lower level 
(CD14dim). The CD14dim monocytes expressed 
CD16 (FcγRIII) three times as did the CD14high 
El-Gamal et al. 
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monocytes in both cord and adult preparations, 
while its level of expression was significantly 
reduced on cord CD14dim monocytes relative to 
adult CD14dim monocytes27. 
In our series, we found that CD14high CD16+ 
and CD14dim CD16+ cells were significantly higher 
in studied patients in comparison with the control 
group. CD14high CD16+ MO accounted for 44.39± 
23.71% and 46.61 ± 10.81% of all monocytes in the 
group of proven sepsis and early sepsis 
respectively, and accounted for 2.36 ± 1.58% in the 
control group. Skrzeczynska et al.26 reported that 
the CD14high CD16+ population comprised 10-70% 
of all CD16+ MO. Both populations were 
significantly increased in proven sepsis group, 
while CD14dim CD16+ MO were also significantly 
elevated in the group of possible infection, when 
compared to controls.  
We also found that the percentage of CD14high 
CD16+ MO was higher than that of CD14dim CD16+ 
MO in 93% of patients and in all controls. In 
agreement with our results, Skrzeczynska et al.26 
stated that in blood samples of studied children, the 
majority of CD16+ MO showed high expression of 
CD14. This was in contrast to adult blood donors 
where reverse proportions were observed  (J. 
Skrzeczynska, unpublished observation; quoted 
from Skrzeczynska et al.26). The highest proportion 
of CD14high CD16+ MO was observed in patients 
with symptoms of sepsis and in particular in 
patients with positive blood cultures. This was the 
novel finding of Skrzeczynska et al.26 as the 
increased proportion of CD14high  CD16+ MO in 
sepsis has not been reported previously. The 
question remains whether this observation reflects 
general phenomenon or is characteristic for sepsis 
in neonates and small children. The increase of 
CD14high CD16+ MO level may reflect the 
mobilization of this subset from the bone marrow 
during the first year of life, because MO of similar 
phenotype were observed after treatment with 
granulocyte colony-stimulating factor (G-CSF) or 
macrophage colony-stimulating factor (M-CSF)28,29.  
CD14high CD16+ MO include population with 
high expression of CD163 scavenger receptor30. In 
vivo, the development of cells which express this 
scavenger receptor was associated with the healing 
phase of acute inflammatory response and was 
shown to produce anti-inflammatory and 
angiogenic factors31,32. Based on the studies of 
healthy blood donors, CD14dim  CD16+ MO are 
believed to represent a pro-inflammatory, 
macrophage-like subpopulation15,16.  
Concerning the phagocytic activity of MO of 
children with sepsis, Skrzeczynska et al.26 reported 
that the phagocytic activity of CD14+ CD16+ MO 
which prevail in the blood of septic patients was 
comparable with or higher than that of CD14+ 
CD16- MO. However, in their control samples, the 
proportion of cells which phagocytosed bacteria 
within CD14+ CD16+ MO was significantly lower 
than in CD14+ CD16- MO. 
In the current study, neither  CD14+ CD16+ 
MO% nor MFI of CD16+ MO were correlated with 
the age and sex of neonates  neither in the patients 
nor in the control group. CD14+ CD16+ MO % did 
not correlate with markers of neonatal sepsis (Hb, 
TLC, ANC, I/T ratio, platelets and CRP), whereas 
MFI of CD16+ MO showed significant positive 
correlation with the CRP and negative significant 
correlations with platelets count. In agreement with 
our results, Fingerle et al.23 reported that CD14+ 
CD16+ cells did not correlate to sex, age, infection 
focus, leukocyte count or platelet count. Only 
CD14+ CD16+  percentage and body temperature 
showed a striking correlation. However, 
Skrzeczynska et al.26 stated that in neonates and 
small children, the increased proportion of CD14+ 
CD16+ MO correlates with clinical symptoms of 
sepsis. Furthermore, this increase was noted 1-2 
days before blood culture became positive. Nockher 
and Scherberich18 stated that no correlation was 
found between the absolute monocyte blood count 
and the percentage of CD14+ CD16+ monocytes. 
The sensitivity and negative predictive value of 
CD14+ CD16+ MO% and MFI of CD16+ MO were 
higher than that of CRP. Specificity and positive 
predictive value of CD14+ CD16+ MO% were 
similar to those of CRP, whereas those for MFI of 
CD16+  MO were less than those of CRP. This 
excellent negative predictive value can reduce the 
unnecessary use of antibiotic therapy and early 
discharge of at-risk non-infected neonates from 
hospital to reduce nosocomial infection.  
In addition, blood culture which is the gold 
standard for diagnosis of infection has a high false 
negative results and only acquires excellent 
negative values at 36 to 48 hours and the results 
may not be available for 24 to 48 hours after 
treatment decisions must have been made33.  
This agrees with  Messer et al.34 who reported 
that CRP determination was not valuable for early 
diagnosis of infection as its sensitivity in the first 12 
hours was only 51%. Nevertheless, its sensitivity 
improved to 83% after 24 hours. De Bont et al.35 
reported that CRP has a short half life (4-6 hours) 
and a variable lag period between the clinical onset 
of the disease and elevated serum concentration.  
We found that MFI of CD16+ MO was 
significantly high after 48 hours in comparison with 
CD14+ CD16+ monocytes in neonatal sepsis. 
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the initial results in the group of early sepsis 
suggesting that as the infectious process proceeded,  
the expression of CD16 on CD14+ monocytes 
increased with progression of the systemic 
inflammatory process.  
In conclusion, measurement of CD16 
expression on CD14+ monocytes is a rapid and 
efficient test that helps in the diagnosis of neonatal 
sepsis at its early stage and valuable in excluding 
neonatal infection in neonates who are at a risk to 
develop sepsis. So, it helps to reduce the 
unnecessary antibiotics use and to discharge the at-
risk but healthy neonates. Future studies including a 
larger sample size with  repeated determinations of 
CD14+ CD16+ MO% in both fullterm and preterm 
neonates at risk or having sepsis are recommended. 
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